Announced details
Treatment and prevention of multiple sclerosis (MS)
The company has a joint research relationship with the NIH/NINDS under a Cooperative Research and Development Agreement (CRADA), and a strategic and financial advisory relationship with MTS Health Partners.
MTS Health Partners is an investment bank specialising in healthcare. NINDS is a research institute under the National Institutes of Health (NIH).
No impact on the consolidated earnings outlook for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
Journal of Clinical Investigation、Science、Nature
| Item | Details |
|---|---|
| Names of Products / Services Covered | Brincidofovir (BCV) |
| Counterparty | MTS Health Partners; the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) |
| Counterparty overview | MTS Health Partners is an investment bank specialising in healthcare. NINDS is a research institute under the National Institutes of Health (NIH). |
| Relationship with the Company | The company has a joint research relationship with the NIH/NINDS under a Cooperative Research and Development Agreement (CRADA), and a strategic and financial advisory relationship with MTS Health Partners. |
| Applicable area | Treatment and prevention of multiple sclerosis (MS) |
| Impact on Business Performance | No impact on the consolidated earnings outlook for the fiscal year ending December 2026 |
| Source | Journal of Clinical Investigation、Science、Nature |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the joint research with the NIH/NINDS is progressing smoothly, preclinical trials are approaching their final stage, and a transition to human trials is expected.